Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 3 Medical Devices Recommended for Approval
May 24, 2010
- Eisai: Aricept, Cancer-Related Products Drive Sales Up 2.7%
May 24, 2010
- Taiyo Yakuhin Recalls Another Product
May 24, 2010
- MTPC: Pharma Sales Up 2.2% Driven by Remicade
May 24, 2010
- GSK's Ofatumumab Receives Conditional Approval in EU
May 24, 2010
- DSP: Overseas Subsidiaries Boost Sales
May 24, 2010
- New Indication for Actemra Approved in Europe
May 24, 2010
- Shionogi: Crestor, US Subsidiary Drive Sales Up 22.4%
May 24, 2010
- Korosho Calls For Cautions for ILD in Patients Receiving Statins
May 24, 2010
- Otsuka HD: Sales of Healthcare Business Up 5.6%
May 24, 2010
- GAMMAGARD Improves Cognitive Function in AD Patients in PII: Baxter
May 24, 2010
- BI Expects 1st Approval for Dabigatran for SPAF in Late 2010
May 17, 2010
- Korosho to Ask for Development of 109 Drugs/Indications
May 17, 2010
- Lixisenatide Significantly Reduces HbA1c: sanofi-aventis
May 17, 2010
- 68% of Public “Don't Know About HPV” Survey
May 17, 2010
- WG to Discuss Regulatory Requirements for Regenerative Medicine
May 17, 2010
- Merck Serono Begins Infertility Treatment Education Program
May 17, 2010
- Exforge to Compete with Takeda's Unisia: Mr Anderson of Novartis
May 17, 2010
- GRU to Call For Lifting on Ban on Supply of Information on Unapproved Drugs
May 17, 2010
- New JMA Leadership to Follow Former Leadership's Policies
May 17, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…